ArticleEpilepsia open2018
Brief history of anti-seizure drug development.
Article in Epilepsia open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Phenytoin Derivatives as Antagonists of AMPA Receptors and Voltage-Gated Sodium Channels: A Structure-Function Study.International journal of molecular sciences · 2026Article
- Review
- Treatment patterns and adverse events of antiseizure medications among adult patients with epilepsy: a single centre observational cross-sectional study in Northern Sri Lanka.BMC neurology · 2026Observational
- Recent Applications of Hydantoins in Drug Discovery: Updates (2019~Present).Molecules (Basel, Switzerland) · 2026Review
- Commonalities in gene expression and methylation changes across two rat models of acquired epilepsy.Scientific reports · 2026Article
- The Evolving Role of Mesenchymal Stem Cells and Their Exosomes in Epilepsy Management: From Bench to Bedside.Stem cells international · 2026Review
- Recent Advances in Therapeutic Potential of Dual-Acting Aromatase/COX-2.Anti-cancer agents in medicinal chemistry · 2026Review
- Recent Advances in the Management of Seizures in Children.Paediatric drugs · 2026Review
- Visual detection of seizures in mice using supervised machine learning.Cell reports methods · 2025Article
- Antiepileptic Drug Combinations for Epilepsy: Mechanisms, Clinical Strategies, and Future Prospects.International journal of molecular sciences · 2025Review
- Phytocannabinoids restore seizure-induced alterations in emotional behaviour in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Antiseizure Medications: Advancements, Challenges, and Prospects in Drug Development.Current neuropharmacology · 2025Review
- Role of Chalcogenides in Sensitive Therapeutic Drug Monitoring Using Laser Desorption and Ionization.ACS nano · 2024Article
- Synthesis and Psychotropic Properties of Novel Condensed Triazines for Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Visual detection of seizures in mice using supervised machine learning.bioRxiv : the preprint server for biology · 2024Article
- Paradigm shift required for translational research on the brain.Experimental & molecular medicine · 2024Review
- Drug resistant epilepsy and ketogenic diet: A narrative review of mechanisms of action.World neurosurgery: X · 2024Review
- Seizure event detection using intravital two-photon calcium imaging data.Neurophotonics · 2024Article
- Review
- Retention Rates and Successful Treatment with Antiseizure Medications in Newly-Diagnosed Epilepsy Patients.Yonsei medical journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The mainstay of therapy for epilepsy is anti-seizure drugs (ASDs, also referred to as anticonvulsants and anti-epileptic medications). Through much of the past century, only a handful for ASDs were available for clinical use. However, with the creation of the U.S. National Institutes of Health/National Institute of Neurological Disorders and Stroke (NINDS)-sponsored Anticonvulsant Screening Program (ASP), coupled with the emergence of high-throughput screening platforms and methodologies, and advances in our understanding of the fundamental neurobiology of epilepsy, ASD development has greatly accelerated over the past 25 years. More than 18 new ASDs have been approved for clinical use since the inception of the ASP. Despite this remarkable success and the emergence of drugs possessing more favorable pharmacokinetic profiles that act on novel molecular targets, there has been increasing recognition that the paradigms for drug discovery have not yielded significant improvements in therapeutic efficacy, and that disease modification (i.e., anti-epileptogenesis), among other challenges, must be addressed. Thus, with the renewed framework and mission of improving the lives of people with epilepsy, the name of the ASP was changed to the Epilepsy Therapy Screening Program (ETSP). This review briefly summarizes the history of ASD development and outlines some of the challenges and opportunities for the next generation of drug therapies for the epilepsy field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.